Objective-Alterations of the chemokine receptor CX3CR1 gene were associated with a reduced risk of myocardial infarction in human and limited atherosclerosis in mice. In this study, we addressed whether CX3CR1 antagonists are potential therapeutic tools to limit acute and chronic inflammatory processes in atherosclerosis. Approach and Results-Treatment with F1, an amino terminus-modified CX3CR1 ligand endowed with CX3CR1 antagonist activity, reduced the extent of atherosclerotic lesions in both Apoe −/− and Ldlr −/− proatherogenic mouse models. Macrophage accumulation in the aortic sinus was reduced in F1-treated Apoe −/− mice but the macrophage density of the lesions was similar in F1-treated and control mice. Both in vitro and in vivo F1 treatment reduced CX3CR1-dependent inflammatory monocyte adhesion, potentially limiting their recruitment. In addition, F1-treated Apoe −/− mice displayed reduced numbers of blood inflammatory monocytes, whereas resident monocyte numbers remained unchanged. Both in vitro and in vivo F1 treatment reduced CX3CR1-dependent inflammatory monocyte survival. Finally, F1 treatment of Apoe −/− mice with advanced atherosclerosis led to smaller lesions than untreated mice but without reverting to the initial phenotype.
A therosclerosis is a chronic inflammatory disease of the arterial wall that develops in a setting combining lipid metabolism and immune response disturbances. 1 The hallmark feature of atherosclerosis is the formation of atherosclerotic lesions that result from the accumulation of fatty materials, such as cholesterol and lipid-rich lipoprotein (low-density lipoprotein [LDL]), and of inflammatory leukocytes (mostly macrophages) in the subendothelial space of the vessel wall. 2, 3 The proposed pathological mechanisms leading to plaque formation rely on the recruitment of intimal macrophages that accumulate modified LDL and convert them into lipid-rich foam cells, releasing proinflammatory and cytotoxic molecules. The proinflammatory environment further promotes plaque progression to more advanced and complex lesions, which are prone to rupture.
Most current therapeutic drugs target the best-documented atherogenesis-promoting risk factors. Examples of this include the treatment of dyslipidemia with inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase such as statins 4 and the regulation of high blood pressure with inhibitors of angiotensin-converting enzyme. 5 Although statins have a pronounced anti-inflammatory activity by reducing the plasma level of the inflammation marker C-reactive protein, 6 they are not designed to control inflammation. In fact, these drugs do not specifically or directly target recruitment of leukocytes into the lesions. Among the many different leukocyte populations that infiltrate atherosclerotic lesions, 7 macrophages seemed to be the main cellular species. 8 The pathogenic role of macrophages was mostly inferred from animal models. Osteopetrotic mice with spontaneous deficiency in monocyte colony-stimulating factor and circulating monocytes showed a profound reduction in atherosclerosis resulting from a marked decrease in macrophage accumulation within lesions. 9 Similarly, monocyte depletion using toxic agents, such as clodronate 10 and diphtheria toxin, in CD11b-diphteria toxin receptor transgenic mice 11 led to reduced atherosclerosis.
Two major monocyte subsets can be distinguished in the blood based on differential expression of the chemokine October 2013 receptors CCR2 and CX3CR1. The inflammatory monocytes express high levels of CCR2 but low levels of CX3CR1 (CCR2 + CX3CR1 lo ), whereas the resident monocytes have a reciprocal marker expression profile (CCR2 -CX3CR1 hi ). Inflammatory monocytes rapidly enter sites of inflammation where they give rise to macrophages or antigen-presenting cells. [12] [13] [14] Resident monocytes enter lymphoid and non-lymphoid organs under homeostatic conditions, and patrol the vascular endothelium in a CX3CR1-dependent manner. 15 The former subset dominates hypercholesterolemia-associated monocytosis 14, 16 and seems to be recruited into atherosclerotic arteries primarily through CCR2. 14 The main CCR2 ligand seems to be important during early atherogenesis, whereas the unique CX3CR1 ligand (CX3CL1) is thought to be involved in the progression of the disease. Atherosclerosis is attenuated in Ccr2 −/− , 17 Ccl2 −/− , 18 Cx3cl1 −/− , 19 and in Cx3cr1 −/− mice 20, 21 but combined deficiencies of these axes lead to an even more drastic reduction in atherosclerotic lesions, 22, 23 confirming a nonredundant role of these chemokine axes in atherosclerosis. In addition, pharmacological inhibition of CCR5, another chemokine receptor involved in leukocyte recruitment, resulted in an almost entire abrogation of atherosclerosis in Cx3cr1 −/− Ccl2 −/− Apoe −/− mice. 22 Targeting the chemokine system to prevent or to reduce atherosclerosis seems to be of great interest. However, blocking CCR2 with antagonists was poorly efficient on aortic lesions 24, 25 but led to a significant reduction in monocytosis. Blocking CCR5 limits the progression of atherosclerosis 26, 27 probably by regulating leukocyte recruitment and systemic inflammation. To date, no CX3CR1 antagonist has been tested in atherosclerosis. We recently developed an amino terminus-modified CX3CL1 (N-terminal sequence ILDNGVS replacing QHHGVT of the human CX3CL1) endowed with CX3CR1 antagonist activity reducing both CX3CR1-dependent migration and adhesion 28 and evaluated its efficacy in murine models of atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Pharmacological Inhibition of CX3CR1 Reduces Atherosclerotic Plaque Development
To assess the therapeutic potential of the CX3CR1 antagonist (F1) on atherosclerotic lesion development, Apoe −/− mice were fed on high-fat diet (HFD) for 15 weeks (Figure 1 ) and treated for the last 10 weeks of the HFD, 3× a week by intraperitoneal injection of 50 µg of F1 or saline solution. Differential interference contrast microscopy was used to reveal atherosclerotic lesions in the aorta of saline-and F1-treated Apoe −/− mice ( Figure 1A ). Quantitative computer-assisted image analysis showed a 40% decrease of the lesion area after F1 treatment ( Figure 1B) . The F1 antiatherogenic effect was similar to the atheroprotection observed in Cx3cr1 gfp/gfp Apoe −/− mice with the green fluorescent protein (GFP) being expressed under the control of the CX3CR1 promoter. 29 In addition, F1 effect was lost in the Cx3cr1-deficient mice. Lipid staining with oil Red O (ORO) of aortic sinus sections revealed a marked reduction in atherosclerotic lesions in mice treated with F1 compared with saline-treated mice ( Figure 1C ). Treatment resulted in a 30% decrease in the extent of aortic sinus positively stained with ORO ( Figure 1D ; with lesion volumes of 0.32±0.03 mm 3 and 0.22±0.02 mm 3 for saline-and F1-treated Apoe −/− mice, respectively). To reduce errors induced by sectioning angle, results were expressed as the percentage of the cross-sectional vessel volume stained with ORO. About a 25% reduction was still observed in the F1-treated group compared with controls after normalizing the lesion size volume to the lumen size volume (P<0.05; 16.0±1.3% for the saline Apoe −/− mice versus 11.9±1.2% for the F1-treated Apoe −/− mice), confirming a specific effect of F1 on the atherosclerotic lesion volume. To investigate in more details the stage of the atherosclerotic lesions, collagen content and apoptosis were analyzed by Sirius red and terminal deoxynucleotidyl transferase deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling nick end labeling staining, respectively. Lesions from salineand F1-treated mice were indistinguishable for both markers ( Figure I in the online-only Data Supplement), suggesting that lesion stage was unaltered by F1 treatment. To confirm that the F1 antiatherosclerotic effect was not model dependent, the Ldlr −/− mice were fed with HFD and treated with the same regimen. F1 treatment in Ldlr −/− mice decreased by 27% the extent of the lesion according to ORO staining ( Figure 1E ; with lesions volumes of 0.03±0.002 mm 3 and 0.02±0.003 mm 3 for saline-and F1-treated Ldlr −/− mice, respectively). After normalization of the lesion volume against the lumen volume, the F1 antiatherosclerotic effect was ≈40% (P<0.01; 2.3±0.3% and 1.3±0.2% for the saline-and F1-treated Ldlr −/− mice, respectively). Lesion size is correlated with dyslipidemia and we, therefore, evaluated the effect of F1 on lipidemia. F1 treatment had no or only a minor effect on the seric total cholesterol, the free cholesterol, the triglycerides, and lipoproteins in both proatherogenic models ( Figure II in the online-only Data Supplement). Globally, these results indicate that F1 limited the atherosclerotic lesion development in 2 different models of atherogenesis and suggest that the F1 antiatherosclerotic effect may be independent of dyslipidemia regulation.
Pharmacological Inhibition of CX3CR1 Attenuates Macrophage Lesion Accumulation
Assuming a role of CX3CL1 on monocyte recruitment, we assessed the effect of F1 on the macrophage content of the lesions in the Apoe −/− model ( Figure 2 ). Total macrophage accumulation, assessed by monocyte/macrophage-2 staining, was reduced in F1-treated Apoe −/− mice compared with saline-treated Apoe −/− mice (Figure 2A and 2B). The inhibition reached ≈40% ( Figure 2C ). However, the macrophage density within the lesion, evaluated by the ratio of the monocyte/macrophage-2 staining to the ORO staining, was not affected by F1 ( Figure 2D ). Similar results were observed using CX3CR1 staining to assess CX3CR1-positive macrophages ( Figure 2E -2H) with an absolute reduction of the CX3CR1-stained surface by 40% in F1-treated mice ( Figure 2E and 2F with quantification in Figure 2G ) and no change when expressed as a ratio to the lesion area ( Figure 2H ). These results indicate that F1 limited macrophage accumulation in the aortic sinus without altering macrophage density.
Both In Vitro and In Vivo F1 Treatment Inhibits CX3CR1-Dependent Monocyte Adhesion
To identify F1 cellular target in vivo, fluorescent-labeled F1 (FluoF1) was injected intravenously in Cx3cr1 gfp/+ mice. FluoF1 was selectively detected on monocytes ( Figure 3A ) but not on polymorphonuclear neutrophils or lymphocytes except natural killer cells (data not shown). Interestingly, FluoF1 staining was more intense on GFP low /ly6C high monocytes (mean fluorescence intensity=22.1±0.2) compared with GFP high /ly6C low monocytes (mean fluorescence intensity=41.05±3.45). FluoF1 staining fainted rapidly over time and could not be detected 4 hours after injection ( Figure 3B ). FluoF1 could not be detected in plasma or serum. Intraperitoneal injection of FluoF1 leads to fluorescent accumulation in resident macrophages but no staining could be detected in serum, plasma, or circulating cells (data not shown). The CX3CR1 ligand is strongly produced by atherosclerotic lesions and participates in the capture of blood monocytes. Thus, a CX3CR1 antagonist may inhibit CX3CR1positive cell adhesion to CX3CL1-expressing surfaces. As shown in Figure 3C , bone marrow cells from Cx3cr1 gfp/+ mice strongly adhered to a CX3CL1-coated surface. The GFP intensity was used to discriminate GFP high from GFP low adherent cells. Computer-assisted image analysis was used to quantify GFP high from GFP low adherent cells as shown in Figure 3D . Bone marrow cells from Cx3cr1 gfp/+ mice were treated with F1 and exposed to a CX3CL1-coated surface ( Figure 3E ). As expected, GFP high cells adhered more efficiently to CX3CL1-coated surfaces than GFP low cells. F1 almost abrogated CX3CR1-dependent adhesion to coated CX3CL1 of both GFP + subpopulations. Interestingly, GFP high cells from saline-or F1-treated Cx3cr1 gfp/+ Apoe −/− mice adhered similarly ( Figure 3F ), whereas GFP low cells were ≈40% less adherent than those from saline-treated Cx3cr1 gfp/+ Apoe −/− mice. We conclude that both in vitro and in vivo F1 treatments attenuated CX3CR1-dependent cell adhesion, thus limiting monocyte recruitment to the lesion site.
F1 Reduces Monocytosis in Apoe −/− Mice
Because F1 treatment reduced monocyte adhesion, long-term treatment in mice may lead to increased monocytosis by preventing monocytes to infiltrate the atherosclerotic lesions. We, therefore, decided to investigate the F1 effect on blood monocytes ( Figure 4) . The inflammatory and resident monocyte subpopulations were identified by flow cytometry as low side scatter, high forward scatter cells, expressing high level of CD11b and either high or low levels of the myeloid antigen 7/4 ( Figure 4A , right). Polymorphonuclear neutrophils and natural killer cells were identified on the basis of the expression of specific markers, Ly6G and NK1.1, respectively ( Figure 4A,  left) . Surprisingly, F1 treatment reduced by 50% the absolute numbers of 7/4 hi or inflammatory monocytes in Apoe −/− mice ( Figure 4B ; with 7/4 hi numbers of 12.55±1.9×10 3 /mL and 6.9±1.7×10 3 /mL for saline-and F1-treated Apoe −/− mice, respectively), whereas the number of 7/4 lo or resident monocytes was not altered ( Figure 4C ; with 7/4 lo numbers of 36.2±4.7×10 3 /mL and 33.3±4.4×10 3 /mL for saline-and F1-treated Apoe −/− mice, respectively). Accordingly, the frequency of 7/4 hi monocytes was reduced (P<0.05; 2.4±0.3% versus 1.3±0.2% for saline-and F1-treated Apoe −/− mice, respectively), whereas the frequency of 7/4 lo monocytes was unaltered (P=ns; 6.6±0.9% versus 5.8±0.7% for saline-and F1-treated Apoe −/− mice, respectively). Polymorphonuclear neutrophils and natural killer cell numbers were not affected by F1 treatment ( Figure 4D and 4E ). In the Ldlr −/− mice, similar results were observed with F1-limiting monocytosis of 7/4 hi monocytes (P<0.005; 10.4±0.1×10 3 /mL versus 5.9±0.7×10 3 /mL monocytes for saline-and F1-treated Ldlr −/− mice, respectively) without any significant effect on 7/4 lo monocytes (P=ns; 20.2±0.3×10 3 /mL versus 16.4±0.3×10 3 /mL for saline-and F1-treated Ldlr −/− mice, respectively). In addition, neither the frequency nor the number of monocyte subpopulations was significantly affected by F1 treatment in the bone marrow and in the spleen (data not shown). Taken together, our data show that F1 treatment specifically decreased the size of the blood 7/4 hi monocyte population and dissociated the monocytosis from lesion progression suggesting an antiatherogenic role of F1 through changes in monocyte functions.
F1 Treatment Reduces CX3CR1-Dependent Monocyte Survival
Interactions between CX3CR1 and its ligand provide an essential survival signal for monocytes and may participate in atherogenesis. 30 We hypothesized that, in addition to blocking CX3CR1-dependent adhesion, F1 may inhibit a CX3CR1-dependent survival signal ( Figure 5 ). Bone marrow cells taken from C57bl/6 mice were grown in FCS-free conditions and live cells were identified using flow cytometry by the exclusion of the propidium iodide ( Figure 5A ). CX3CL1, at 100 nmol/L, increased 7/4 high and 7/4 low monocytes survival by ≈35% ( Figure 5B ). In contrast, F1 reduced cell survival by ≈40% for both monocyte subpopulations. To test whether in vivo F1 treatment may alter cell survival, monocyte survival was compared in saline-and F1-treated Apoe −/− mice. The number of live 7/4 high monocytes was reduced by ≈50% in F1-treated Apoe −/− mice compared with untreated control mice ( Figure 5C ). In contrast, 7/4 low monocyte survival was similar after in saline-and F1-treated mice. Overall, our results show that both in vitro and in vivo F1 treatment reduced CX3CR1-dependent inflammatory monocyte survival, consistent with the reduction in monocytosis observed after long-term F1 treatment.
F1 Treatment Slows Down the Development of Advanced Atherosclerotic Lesions
Because F1 displayed strong anti-adhesion and anti-survival properties, we thought that it could represent an interesting tool for limiting the development of more advanced atherogenic lesions. To address this question, F1 treatment of Apoe −/− mice was delayed by 3 weeks (from 5 to 8 weeks) after HFD and the progression of the atherosclerotic was compared between 8 and 16 weeks of HFD ( Figure 6A ). ORO staining showed a significant increase in the lesion volume of the 16-week HFD Figure 3 . Both in vitro and in vivo F1 treatments inhibit CX3CR1-dependent monocyte adhesion. FluoF1 cellular distribution (A) and clearance (B) after intravenous injection. C, Representative photomicrography of bone marrow myeloid cells isolated from Cx3cr1 gfp/+ mice exposed to immobilized CX3CL1. Scale bar, 70 µm. Inset, Green fluorescent protein (GFP) intensity was analyzed and revealed 2 cell subpopulations. D, Volume rendering mask was applied to the representative photomicrography and adherent cells subpopulations were counted. E, Bone marrow myeloid cells isolated from Cx3cr1 gfp/+ mice were treated or not with F1 and exposed to immobilized CX3CL1. Data represent the percentage of GFP high and GFP low adherent cells compared with the number of GFP + cell subsets loaded in the well. F, Cx3cr1 gfp/+ Apoe −/− mice were treated with F1 or saline, and bone marrow myeloid cells were isolated and exposed to immobilized CX3CL1. Data represent the percentage of GFP high and GFP low adherent cells compared with the number of GFP + cell subsets loaded in the well. Non-coated wells defined nonspecific adhesion and was <1%. E and F, Representative of 3 independent experiments run in triplicates. MFI indicates mean fluorescence intensity. October 2013 Apoe −/− mice (0.24±0.03 mm 3 ) compared with the 8-week HFD Apoe −/− mice (0.12±0.03×10 3 mm 3 ). In the F1-treated group, the lesion volumes did not significantly progress between 8 and 16 weeks (0.19±0.03 mm 3 ) and were reduced by ≈20% compared with the 16-week HFD saline-treated mice. As expected, F1 treatment reduced by 40% the absolute number of 7/4 hi monocytes in Apoe −/− mice ( Figure 6B ; 17.8±4.6×10 3 /mL versus 10.6±2.3×10 3 /mL for saline-and F1-treated mice, respectively) with no effect on the 7/4 lo monocytes (P=ns; 43.0±6.6×10 3 /mL versus 43.6±12.3×10 3 /mL monocytes for saline-and F1-treated mice, respectively). We conclude that F1 acts as a potent inhibitor of atherosclerosis progression probably by controlling monocytosis.
Discussion
Here, we have shown for the first time that pharmacological inhibition of CX3CR1 in murine models of atherogenesis led to reduced atherosclerotic lesion development and attenuated monocytosis. The antiatherogenic potency of CX3CR1 blockade was associated with reduced CX3CR1-dependent adhesion and survival of inflammatory monocytes. This work reveals that controlling monocytosis by blocking CX3CR1 may help prevent atherogenesis.
Although convincing evidence has validated the key role of chemokine receptors in promoting atherosclerosis, very few studies have used chemokine receptor antagonists to characterize their proatherogenic functions. Indeed, their role has essentially been inferred from studies using genetically deficient mice with chemokine or chemokine receptor gene deletion. 31, 32 The most studied chemokines regarding atherosclerosis are those controlling monocyte redistribution, as the prevailing model for lesion development proposed that local production of inflammatory chemokines promotes recruitment of monocytes into the intima and their differentiation into macrophages. For these reasons, mice deficient for genes encoding CCR2, CCR5, and CX3CR1 have been instrumental and showed that individual deletion of these genes resulted in a decrease in atherosclerotic lesions. 17, 20, 21, 33 However, none of these genetic deficiencies resulted in the abrogation of atherosclerotic lesions or of macrophage accumulation indicating that a complex network of recruitment signals is at work in atherogenesis. Indeed, multiple chemokine receptors acting in concert to orchestrate the migration of monocyte subpopulations were identified 14, 22, 23 and showed that CCR2, CX3CR1, and CCR5 play independent and additive roles in atherogenesis. Accordingly, antagonists blocking CCR2 25 and CCR5 26, 27 only partially prevented progression of atherosclerotic lesions and macrophage accumulation. To date, no study has assessed CX3CR1 blockade in atherogenesis models.
The chemokine-based CX3CR1 antagonist that we have developed efficiently limited atherosclerotic lesion development both in Apoe −/− and in Ldlr −/− proatherogenic murine models, confirming the role of CX3CR1 in atherogenesis. The extent of inhibition, in terms of lipid deposition and macrophage accumulation, was moderate (30%-50%) but consistent with data obtained in Cx3cr1 −/− Apoe −/− mice. 20, 21 This indicates that treatment may be optimal. F1 antiatherogenic effect was lost in Cx3cr1-deficient mice indicating that F1 action was CX3CR1 dependent and was not because of F1 contamination. However, macrophage density within the lesions was similar between saline-and F1-treated mice confirming the existence of CX3CR1-independent recruitment pathways controlling macrophage accumulation in the lesion. 14, 22, 23 The mechanistic role of CX3CR1 in atherosclerotic lesion progression remains highly debated and data argue for its involvement in monocyte recruitment, 34 platelet-monocyte complex formation, 35 dendritic cell accumulation, 36 smooth muscle cell migration, 37 and monocyte survival. 30 We assumed that because the sole ligand of CX3CR1 is a membranetethered chemokine, it might have a crucial role in capturing monocytes from the blood. Indeed, monocytes exposed in vivo or in vitro to F1 have much less propensity to adhere to CX3CL1-expressing surfaces, therefore, reducing their ability to migrate into the lesions. It remained to elucidate why only adhesion of GFP low bone marrow cells was inhibited after mice treatment and not that of GFP high bone marrow cells. Cellular distribution of these 2 monocyte subtypes may differ allowing selective antagonist accessibility.
Because F1 treatment reduced monocyte adhesion, preventing a portion of monocytes from infiltrating the atherosclerotic lesion, we were expecting that long-term treatment of mice would lead to increased monocytosis. In contrast, we observed that long-term F1 treatment led to reduced monocytosis, specifically affecting inflammatory monocytes. We postulated that F1 might reduce monocyte survival by blocking the antiapoptotic effect of CX3CL1, as previously reported. 30 Our data indicate that only inflammatory monocytes exposed in vivo or in vitro to F1 have impaired survival capacity. In addition, Apoe −/− and Ldlr −/− long-term F1 treatment resulted in a 30% reduction in inflammatory monocyte numbers, while having no effect on resident monocytes. These results seemed to contradict those obtained in Cx3cr1-deficient mice (Cx3cr1 gfp/gfp ), where a 3-fold reduction in resident monocyte numbers was observed (as compared with wild type) with no alteration in the number of inflammatory monocytes. 30 Such a difference in phenotype, which arises from the comparison of genetic deletion to pharmacological inhibition, is not unique and may exist for several reasons. A common cause of discrepancies is compensatory mechanisms that take place in gene-deleted mice during development. Another issue in this work is the potential existence of other sites of action of the antagonist that we have not as yet been able to identify. Future studies looking notably at the bioavailability of F1 need to be performed.
The effects of F1 treatment solely on inflammatory monocytes and not on resident monocytes proved particularly intriguing because the former express lower levels of CX3CR1 than the latter. It was expected that monocytes exhibiting strong expression of CX3CR1, the so-called resident monocytes, would be more sensitive to F1. However, previous work from Tacke et al 14 has shown that (1) blood monocytosis was skewed toward an increase in inflammatory monocytes in Apoe −/− mice fed on HFD, (2) inflammatory monocytes accumulated in atherosclerotic lesions, whereas resident monocytes entered less frequently, and (3) inflammatory monocytes unexpectedly required CX3CR1 in addition to CCR2 and CCR5 to accumulate within plaques. This study proposes CX3CR1 blockade as an effective treatment, aiming to limit recruitment of inflammatory monocytes while keeping intact CCR2dependent functions. Our data are in perfect agreement with this study but the reasons for this skewing still remain elusive.
Our data indicate that F1 does affect not only the number of circulating monocytes but also their atherogenic properties. Indeed, we confirmed that both in vitro and in vivo monocyte treatment with the CX3CR1 antagonist reduced the CX3CR1-dependent adherence and the survival of myeloid populations, in accordance with previous reports. We cannot exclude the fact that reduced adherence is because of the induction of cell death, but the inhibition of cell adherence in vitro was immediate, whereas reduction of cell survival was only detectable after longer treatment, suggesting that inhibition of adherence preceded cell death. Although we cannot rule out the involvement of F1 in myeloid precursor modulation, neither the frequency nor the numbers of monocytes in the bone marrow and in the spleen were affected by F1 treatment, indicating that F1 may only act on circulating monocytes. CX3CR1 gene polymorphism is associated with a reduced risk of coronary artery diseases. [38] [39] [40] The underlying mechanism might involve less efficient interaction between monocytes and injured endothelium in subjects exposed to coronary risk factors. The important issue is whether such finding could be useful to develop CX3CR1-based therapeutic approaches. Here, we provide evidences in murine models of atherosclerosis that altering CX3CR1-dependent pathways is atheroprotective.
In conclusion, we show that F1 represents a potent inhibitor of the CX3CR1 axis and a promising compound for the prevention of atherogenesis. F1 was able to not only limit atherosclerosis progression but also prevent the development of more advanced lesions. These results suggest that agents blocking the CX3CL1-CX3CR1 interaction might help to prevent the onset and progression of atherosclerotic lesions. By limiting monocytosis, CX3CR1 inhibition may, therefore, be an alternative or complementary therapy to the more widely used lipid-lowering drugs in the treatment of atherosclerosis. Inflammation contributes to all phases of atherosclerosis, from initiation and progression to the final complications. Monocytes and macrophages are essential leukocytes in atherogenesis. Many studies have shown that chemokine receptors, such as CCR2, CCR5, and CX3CR1, are implicated in the development of atherosclerotic lesions by controlling monocyte redistribution from blood to lesions. Our study provides experimental evidences that pharmacological inhibition of CX3CR1 using a peptide antagonist named F1 has potential therapeutic application to prevent the onset and progression of atherosclerotic lesions. F1 treatment in mice reduced atherosclerotic lesion development and attenuated monocytosis. F1 target a specific subset of monocytes involved in the development of the lesions by the alteration of their adherence and survival. CX3CR1 inhibition may, therefore, be an alternative or complementary therapy to the more widely used lipid-lowering drugs in the treatment of atherosclerosis.
Significance
